Healthcare · NYSE/NASDAQ: GILD
GILEAD SCIENCES, INC.
Drug Manufacturers—General
Market Cap $154.33B
Verdict: Average
Quality Scores
Multi-Bagger
58/100
Compounder Quality
76/100
Management Credibility
68/100
Governance
88/100
Cash Flow Quality
92/100
AI Summary
Gilead Sciences is transitioning from its legacy dominance in Hepatitis C to a diversified oncology and HIV portfolio. The 10-year data reveals a massive revenue reset followed by stabilization; revenue grew from $5.79B in 2018 to nearly $29.4B in 2025, largely due to the integration of Immunomedics and Veklury sales. However, net income exhibits extreme volatility, evidenced by a $480M low in 2024 compared to $8.5B in 2025, reflecting heavy R&D impairments and M&A costs. While the company maintains formidable cash generation, the ROI on its multi-billion dollar acquisitions remains the…
Top Opportunities
- Consistent Cash Flow from Operations (CFO) > $8B/year
- Dominant market share in HIV therapeutics (Biktarvy)
- Strong recovery in net income for FY 2025
Top Risks
- Operating margins significantly lower than 2016 peaks
- Veklury (Covid-19) revenue is volatile and declining
- Significant patent expiration risks for HIV portfolio (2027-2033)
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.